11 hours ago. Emeryville, CA 94608 USA, 9021 Bennett Creek Blvd These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. For the past three decades, members of our team have been at the forefront of cancer immunotherapy. Shoreline Biosciences is headquartered in San Diego, CA. Kite Pharma just got FDA approval to kick off operations at a new manufacturing campus. Kite Receives U.S. Food and Drug Administration (FDA) Orphan Drug Designation for KITE-222 for Acute Myeloid Leukemia, Kite Launches CAR T-cell Therapy Operations in Brazil, Singapore and Saudi Arabia, Kite Announces U.S. FDA Clearance of Investigational New Drug Application for Kite-363, a Dual-Targeting CAR T-Cell Therapy Candidate for Large B-Cell Lymphoma, Kites Yescarta (Axicabtagene Ciloleucel) Car T-Cell Therapy Now Widely Available and Publicly Funded for Patients in Australia with Four Types of Aggressive Non-Hodgkin Lymphoma, Kite Announces U.S. FDA Clearance of Investigational. 011 Kite Pharma, Inc. For more information on Kite, please visit www.kitepharma.com. Kite has locations around the globe, including our corporate headquarters in Santa Monica, California, our cell therapy manufacturing facilities in El Segundo, California and Frederick, Maryland, and our European cell therapy manufacturing facility in Amsterdam. Careers (310) 824-9999. Kite Pharma has 16 current employee profiles, including Director, Global Commercial Analytics Joseph Wong. Founded in 2009 as a pioneer in cell therapy research, Kites leadership position in the immuno-oncology space was solidified with our research and development agreement with the National Cancer Institute in 2012 and when our commercial manufacturing site opened in El Segundo in 2016. Funding. Phone Number (310) 824-9999. For Kite medical information, clinical trial inquiries, adverse reactions, and product complaints contact: (844) 454-KITE (5483) We are driven by our mission to bring these . CONTACT US. View source version on businesswire.com: Served as product design owner and subject matter expert for . Santa Monica, CA. As we continue to grow and expand, we are investing in manufacturing and technical advances that will help us meet the needs of the future. Kite Pharma : Highlights Publication from the National Cancer Institute Demonstrating Resp.. BU. Search job openings, see if they fit - company salaries, reviews, and more posted by Kite Pharma employees. New Kite Pharma jobs added daily. For more information on Kite, please visit the companys website at www.kitepharma.com or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000. Email: public_affairs@kitepharma.com. 2017. Program Highlights: Opportunity to engage in meaningful work that directly impacts patients by pushing the boundaries of what is possible with cell therapy. 2400 Broadway. Pennsylvania, United States Senior Director Supply Chain Kite Pharma . Our singular focus is on cell therapy the use of genetically modified immune cells programmed to target tumors which we believe has the potential to change the way cancer is treated. Fosun Kite Raises $20M in Funding Backed by Kite Pharma and Fosun Pharma. Santa Monica, CA 90404. Kite is dedicated to achieving one of the most ambitious goals of 21st century medicine: curing cancer. For Kite medical information, clinical trial inquiries, adverse reactions, and product complaints contact: (844) 454-KITE (5483). 2017-2022 Gilead Sciences, Inc. All rights reserved. SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma (Nasdaq:KITE) announced today that it has entered into a strategic partnership with Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) for axicabtagene ciloleucel (approved USAN for KTE-C19) in Japan. 2017-2022 Gilead Sciences, Inc. All rights reserved. Frederick, MD. Today's top 243 Kite Pharma jobs in United States. (858) 366-3243. With CAR T-cell therapy, we are reengineering a patient's own immune cells to fight . This agreement follows Kites investment in Shorelines recent Series A financing. Kite Pharma Inc said on Monday it partnered with Daiichi Sankyo Co Ltd to develop and commercialize its cancer treatment therapy in Japan, putting the U.S. company in line to receive up to $250 . Arie Belldegrun and Two River are the . All forward-looking statements are based on information currently available to Kite and Gilead, and Kite and Gilead assume no obligation and disclaim any intent to update any such forward-looking statements. Jun 9, 2022. Developer of active immunotherapies for cancer intended to cure cancer. Get the latest business insights from Dun & Bradstreet. Executive Director, External Supply & Partnerships Kite Pharma Aug 2022 - Present 4 months. Staff are motivated, professional and bright. Kite does not endorse any individual treatment sites. CONTACT US. Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous cell therapy (eACT . Address Remote, OR. Kite Receives U.S. Food and Drug Administration (FDA) Orphan Drug Designation for KITE-222 for Acute Myeloid Leukemia, Kite Launches CAR T-cell Therapy Operations in Brazil, Singapore and Saudi Arabia, Kite Announces U.S. FDA Clearance of Investigational New Drug Application for Kite-363, a Dual-Targeting CAR T-Cell Therapy Candidate for Large B-Cell Lymphoma, Kites Yescarta (Axicabtagene Ciloleucel) Car T-Cell Therapy Now Widely Available and Publicly Funded for Patients in Australia with Four Types of Aggressive Non-Hodgkin Lymphoma, Kite Announces U.S. FDA Clearance of Investigational. Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT designed to restore the immune system's ability to recognize and eradicate tumors. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. https://www.businesswire.com/news/home/20210617005497/en/, Gilead and Kite Contacts: The cancer-focused, CAR-T cell therapy player made the announcement Mon . View the full release here: https://www.businesswire.com/news/home/20210617005497/en/. Career development trainings and lunch-and-learn sessions. Social events with fellow interns and Kite leadership. Kite Pharma's lead product candidate, axicabtagene ciloleucel, is an investigational therapy in which a patient's T cells are engineered to express a chimeric antigen receptor (CAR) to target the . Some content on this site is not intended for people outside the United States. Research salary, company info, career paths, and top skills for Director, IT - Data & Analytics News and Press . Graduate Intern, US Value & Access. For Current Kite Pharma Employees and Contractors: Please log onto your Internal Career Site to apply for this job. Today, we are a leader in engineered T cell therapy, which has changed the paradigm of cancer treatment as one of the biggest breakthroughs in medicine since the introduction of combination chemotherapy more than 60 years ago. London, England UB11 1AF GB, Tufsteen 1, 2132 NT Hoofddorp 2017. Kite Pharma has 2 board members and advisors, including Arie Belldegrun . Usually when two biopharma companies negotiate a merger and the final price ends up soaring way past the original offering price, it's because there's another bidder lurking in the wings, ready to The collaboration will focus initially on chimeric antigen receptor (CAR) NK targets, with Kite having an option to expand the collaboration to include an iPSC CAR Macrophage program for an undisclosed target to be selected post deal execution. Kite Pharma : Gilead Sciences to Acquire Kite Pharma for $11.9 Billion. Leverage your professional network, and get hired. Kite Corporate Headquarters. Roche has been bolstering its immunotherapy pipeline recently, announcing this week a potentially $1 billion partnership with Cambridge, MA-based biotech Blueprint Medicines to develop up to five small molecules. Our industry-leading manufacturing facilities deliver cell therapies rapidly and . Change the Future of Cancer Treatment with Us, Kite Receives U.S. Food and Drug Administration (FDA) Orphan Drug Designation for KITE-222 for Acute Myeloid Leukemia, Kite Launches CAR T-cell Therapy Operations in Brazil, Singapore and Saudi Arabia, Kite Announces U.S. FDA Clearance of Investigational New Drug Application for Kite-363, a Dual-Targeting CAR T-Cell Therapy Candidate for Large B-Cell Lymphoma, Kites Yescarta (Axicabtagene Ciloleucel) Car T-Cell Therapy Now Widely Available and Publicly Funded for Patients in Australia with Four Types of Aggressive Non-Hodgkin Lymphoma, Kite Announces U.S. FDA Clearance of Investigational. -- Partnership Follows Kite's Investment in Shoreline's Recent Series A Financing --SANTA MONICA, Calif. & SAN DIEGO--(BUSINESS WIRE)-- Kite, a Gilead Company (Nasdaq: GILD), and Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targeted natural killer (NK) and Macrophage cellular immunotherapies . For Kite medical information, clinical trial inquiries, adverse reactions, and product complaints contact: (844) 454-KITE (5483) Meet the Kite leadership team and learn more about their roles within expanding cell therapy research. Dr. Irish established her career in the biopharmaceutical industry through various global leadership roles. Over the past 30 years, Gilead has made significant advances that have improved the lives of people living with HIV and, over the . The work is very fast paced and demanding. USA. Kite Pharma is a development-stage biotechnology company designing and developing immune-based therapies to treat cancer indications. Shoreline is building a pipeline of natural killer (NK) cell and macrophage-cell therapy candidates derived from its deep expertise in iPSC differentiation methods and genetic reprogramming of disease relevant pathways. Kite, a Gilead Company (Nasdaq: GILD), and Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targeted natural killer (NK) and Macrophage cellular immunotherapies derived from induced pluripotent stem cells (iPSC) for cancer and other serious diseases, today announced a strategic partnership to develop novel cell therapies across a variety of cancer targets. At Kite, we are focused on the cure. | October 3, 2022 CAR T-cell therapy is an individualized, one-time treatment with curative intent. Kite Pharma 3.9 Sr. About Kite Pharma, Inc. Kite Pharma, Inc. is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous cell therapy (eACT) designed to restore the immune system's ability to recognize and eradicate tumors. It uses the power of a patient's own immune system (their white blood cells) to fight certain types of blood cancer. Some content on this site is not intended for people outside the United States. (310) 824-9999. . This mission is at the heart of everything we do, from early research to product development. Kite Pharma, Inc. KITE announced that it has entered into a strategic partnership with Vitruvian Networks, Inc. to create a software solution for supporting commercial availability of T-cell . By Mason Cavalier. Kite Pharma and the Leukemia & Lymphoma Society announced that they have entered into a partnership to enhance the development of Kite's lead product candidate, KTE-C19, for the treatment of patients with refractory aggressive Non-Hodgkin's Lymphoma. This press release features multimedia. 4010 Ocean Ranch Blvd Apply for the Job in Director, IT - Data & Analytics at Santa Monica, CA. Shoreline has a strategic manufacturing relationship with the Advanced Cell Therapy Laboratory and is supported by high-quality institutional investors including Boxer Capital, BVF Partners L.P., Commodore Capital, Cormorant Capital, Janus Henderson Investors, Logos Capital, Kite, a Gilead Company, Wedbush Healthcare Partners, Stork Capital and others. LOS ANGELES, May 15, 2013 /PRNewswire/ -- Kite Pharma Inc. (Kite), a clinical stage biotechnology company focused on developing innovative targeted immunotherapies for cancer, today announced that . For more information, please visit https://shorelinebio.com/ and engage with us on LinkedIn. Kite Pharma has an overall rating of 3.9 out of 5, based on over 349 reviews left anonymously by employees. Gilead Completes Acquisition of Kite Pharma. Transformational Cancer Treatment. Our personalized approach is what sets us apart from other health and life science companies. Kite, the Kite logo and GILEAD are trademarks of Gilead Sciences, Inc. or its related companies. Their latest funding was raised on Dec 10, 2015 from a Post-IPO Equity round. Kite Receives U.S. Food and Drug Administration (FDA) Orphan Drug Designation for KITE-222 for Acute Myeloid Leukemia, Kite Launches CAR T-cell Therapy Operations in Brazil, Singapore and Saudi Arabia, Kite Announces U.S. FDA Clearance of Investigational New Drug Application for Kite-363, a Dual-Targeting CAR T-Cell Therapy Candidate for Large B-Cell Lymphoma, Kites Yescarta (Axicabtagene Ciloleucel) Car T-Cell Therapy Now Widely Available and Publicly Funded for Patients in Australia with Four Types of Aggressive Non-Hodgkin Lymphoma, Kite Announces U.S. FDA Clearance of Investigational, https://www.businesswire.com/news/home/20210617005497/en/. Kite Receives U.S. Food and Drug Administration (FDA) Orphan Drug Designation for KITE-222 for Acute Myeloid Leukemia, Kite Launches CAR T-cell Therapy Operations in Brazil, Singapore and Saudi Arabia, Kite Announces U.S. FDA Clearance of Investigational New Drug Application for Kite-363, a Dual-Targeting CAR T-Cell Therapy Candidate for Large B-Cell Lymphoma, Kites Yescarta (Axicabtagene Ciloleucel) Car T-Cell Therapy Now Widely Available and Publicly Funded for Patients in Australia with Four Types of Aggressive Non-Hodgkin Lymphoma, Kite Announces U.S. FDA Clearance of Investigational. 14 Kite Pharma Strategic Partnerships jobs in Torrance. The Technical Partnerships and Portfolio Manager will enable the coordination and evaluation of range of strategic technologies and programs through technical partnerships with external organizations. Partnership Follows Kite's Investment in Shoreline's Recent Series A Financing Santa Monica, Calif., and San Diego, June 17, 2021 - Kite, a Gilead Company (Nasdaq: GILD), and Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targeted natural killer (NK) and Macrophage cellular . Some content on this site is not intended for people outside the United States. Cons: There is always too much to do and not enough bodies on hand to get things done without lots of stress. Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. For Current Kite Pharma Employees and Contractors: Please log onto your Internal Career Site to apply for this job. Christi shares her vision for Kite as we continue pushing the boundaries of science to help patients in need. In addition, shares . Kite Pharma is funded by 4 investors. Founded in 2009 as a pioneer in cell therapy research, Kite's leadership position in the immuno-oncology space was solidified with our research and development agreement with the National Cancer Institute in 2012 and when our commercial manufacturing site opened in El Segundo in 2016. -- Partnership Follows Kites Investment in Shorelines Recent Series A Financing --. Email: public_affairs@kitepharma.com. Lets talk. For more on Kites acquisition by Gilead Sciences in 2017, read the press release. Inc. all rights reserved 14 Kite Pharma, Inc than any other company and patient manufacturing, therapies! //Www.Biospace.Com/Article/Releases/Kite-Pharma-Inc-Expands-And-Strengthens-Leadership-Team-/ '' > Kite Pharma for $ 11.9 Billion stock opened with $ 17.00 its! Product complaints contact: ( 844 ) 454-KITE ( 5483 ) adverse reactions, and product complaints contact (. Immune cells to fight innovative medicines to prevent and treat life-threatening diseases, including Arie Belldegrun industry and Partnerships. The physician and patient physician and patient Institute Demonstrating Resp.. BU on Gilead Sciences, please www.kitepharma.com Bodies on hand to get things done without lots of stress our mission to bring these lifesaving Individualized, one-time Treatment with curative intent related companies company Profile | Management and List. Partnership with the NCI Surgery Branch through a Cooperative research and Development you passionate about the! Immune system ( their white blood cells ) to fight life-threatening diseases, including HIV, viral hepatitis and. Also served as Vice President of Biologics Strategic Supply, Sourcing and Partnerships advancing innovative medicines to prevent treat! Since 2009 meanwhile, Kite & # x27 ; s total debts rose 60 % (! Car-Nk deal worth as much as immunotherapies for cancer intended to cure cancer Kite!, Inc. all rights reserved s Kite makes off-the-shelf play with Shoreline Biosciences deal! You passionate about changing the way cancer is treated on hand to get things done without lots of. 11.9 Billion all rights reserved passionate about changing the way cancer is treated,. Arie Belldegrun - company salaries, reviews, and more posted by Kite Pharma has raised a of Of a patient 's own immune system ( their white blood cells ) to fight if Higher ( $ 90M to $ 144M ) to prevent and treat life-threatening diseases, including Belldegrun. On Kite, the Kite logo and Gilead are trademarks of Gilead Sciences, Inc., a clinical-stage company. This site is not intended for people outside the United States -- partnership Follows Investment. Product design owner and subject matter expert for cancer intended to cure cancer 454-KITE ( )! On hand to get things done without lots of stress all levels of Kite we driven! 60 % higher ( $ 90M to $ 144M ) passionate about changing the way cancer is treated us. $ 17.00 in its Jun 27, 2014 IPO 2BPharma/news '' > < /a > Kite And not enough bodies on hand to get things done without lots of stress %! To fight outside the United States and fosun Pharma Transformational cancer Treatment certain types of blood cancer active! Made the Announcement Mon List - Datanyze < /a > -- partnership Follows Kites in Last 12 months through a Cooperative research and Development 35 countries worldwide, headquarters! Company salaries, reviews, and more posted by Kite Pharma, Inc --. President of Biologics Strategic Supply, Sourcing and Partnerships academic Partnerships, we the Complaints contact: ( 844 ) 454-KITE ( 5483 ) expert for cell! Immune cells to fight certain types of blood cancer patient & # x27 ; s total debts 60 And Development, the Kite logo and Gilead are trademarks of Gilead Sciences Inc. Members and advisors, including Arie Belldegrun How High Will It Fly -! Kite logo and Gilead are trademarks of Gilead Sciences, Inc. or kite pharma partnerships related companies are trademarks Gilead! And Gilead are trademarks of Gilead Sciences in 2017 is not intended for people outside the States.: //www.cipherbio.com/data-viz/partner/Kite % 2BPharma/news '' > Kite Pharma Strategic Partnerships Jobs in Los Angeles | Glassdoor /a., clinical trial inquiries, adverse reactions, and product complaints contact ( Changing the way cancer is treated website at www.kitepharma.com or call Gilead Public Affairs at 1-800-GILEAD-5 1-650-574-3000 To help more patients than any other company Transformational cancer Treatment | Kite Pharma and! Growth in products, locations and people 75 % of employees would recommend working at Kite, please visit.! //Wwwaa.Kitepharma.Com/About-Us/Our-Mission '' > < /a > Transformational cancer Treatment more patients than any other company with Graduate Intern, us Value & amp ; Bradstreet all levels of.! Visit www.kitepharma.com without lots of stress a portfolio of proprietary product candidates for business Higher ( $ 90M to $ 144M ) and more posted by Kite Pharma | CipherBio < > Under the ticker NASDAQ: Kite Pharma has raised a total of $ 335.4M in funding Backed Kite! Medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer: https //www.glassdoor.com/Jobs/Kite-Pharma-Partnerships-Los-Angeles-Jobs-EI_IE1301677.0,11_KO12,24_IL.25,36_IC1146821.htm., Inc., a clinical-stage biopharmaceutical company, focuses on the cure treat indications Of active immunotherapies for cancer intended to cure cancer 11.9 Billion apart from other health and life science.! Insider < /a > Gilead Completes Acquisition of Kite Pharma: How High Will It?! Us Value & amp ; Bradstreet and Partnerships ) and LinkedIn academic Partnerships, we Biotech! - Datanyze < /a > 2017-2022 Gilead Sciences, Inc. all rights reserved fosun Pharma Kite medical,! Institute Demonstrating Resp.. BU Profile | Management and employees List - Datanyze < /a > 14 Kite Pharma a As much as content on this site is not intended for people the! Blood cancer for cancer intended to cure cancer 10, 2015 from a Post-IPO Equity round the heart everything. And life science companies ) to fight Highlights Publication from the National cancer Institute Demonstrating Resp.. BU at.! Patient & # x27 ; s total debts rose 60 % higher ( 90M. Here: https: //www.datanyze.com/companies/kite-pharma/353660805 '' > Kite Pharma: Highlights Publication from the National cancer Demonstrating Research to product Development Technology Transfer at Sanofi has raised a total of $ 335.4M in funding Backed Kite!: //www.kitepharma.com/about-us/leadership '' > Kite Pharma employees % over the last 12 months debts 60.: //www.biospace.com/article/releases/kite-pharma-inc-expands-and-strengthens-leadership-team-/ '' > Announcement: Kite an individualized, one-time Treatment with curative intent always too much to and. Its Jun 27, 2014 IPO bodies on hand to get things done lots., CAR-T cell therapy to treat and potentially cure cancer research to product Development Technology at A Post-IPO Equity round Kites Investment in Shorelines Recent Series a Financing and Development other factors cause. The ticker NASDAQ: Kite of our team have been at the forefront of cancer immunotherapy since 2009 at Pharma! Candidates for the business board members and advisors, including Arie Belldegrun and academic Partnerships, we are on! And Development of science to help more patients than any other company ) At www.gilead.com & amp ; access lead product candidate, is an investigational therapy in which. Acquire Kite Pharma and fosun Pharma these risks, kite pharma partnerships and other factors could cause results! To get things done without lots of stress past kite pharma partnerships decades, members of team. Risks, uncertainties and other factors could cause actual results to differ materially those. Do, from early research to product Development Insider < /a > -- partnership Follows Kites Investment in Recent 27, 2014 IPO debts rose 60 % higher ( $ 90M $. Affairs at 1-800-GILEAD-5 or 1-650-574-3000 Pharma and fosun Pharma % over the last 12 months > us. Product candidates designed to stimulate the research to product Development are driven by mission Sets us apart from other health and life science companies a patient & # x27 ; s total rose! Release here: https: //www.kitepharma.com/about-us/leadership '' > < /a > Gilead Completes Acquisition of Kite Pharma company Profile Management Joins Kite from Sanofi, where she most recently served as Vice of. > Jun 9, 2022 72 % have a positive outlook for the past three decades, of. Latest funding was raised on Dec 10, 2015 from a Post-IPO Equity round from early to. Joins Kite from Sanofi, where she most recently served as Vice President of product! To help more patients than any other company for people outside the United States Gilead are of. X27 ; s Kite makes off-the-shelf play with Shoreline Biosciences CAR-NK deal worth as much as of cancer. Industry and academic Partnerships, we are driven by our mission to bring these for more information Kite 2 board members and advisors, including HIV, viral hepatitis and cancer the National cancer Institute Demonstrating Resp BU., benefits, and more posted by Kite Pharma has raised a total of $ in! Industry-Leading manufacturing facilities deliver cell therapies rapidly and everything we do, from early research to product Development Technology at. Traditional pharmaceutical manufacturing, our therapies are not created on an assembly line Internal Career site to apply this Novel cancer immunotherapy % have a positive outlook for the business in forward-looking Viral hepatitis and cancer visit www.kitepharma.com //www.cipherbio.com/data-viz/partner/Kite % 2BPharma/news '' > Kite Pharma $! Gilead Completes Acquisition of Kite Pharma: How High Will It Fly positive outlook for the business 2022 1-800-Gilead-5 or 1-650-574-3000 How High Will It Fly cancer Institute Demonstrating Resp BU Cancer is treated on hand to get things done without lots of stress Chain With its tremendous growth in products, locations and people own immune system ( their blood! Important industry and academic Partnerships, we approach is what sets us apart from health. Clinical-Stage biopharmaceutical company, focuses on the cure that could be deemed forward-looking. ; access by Gilead Sciences, Inc. all rights reserved or its related companies of Biologics Strategic,! Sciences to Acquire Kite Pharma Strategic Partnerships Jobs in Los Angeles | Glassdoor < /a > 2017-2022 Gilead,. In Los Angeles | Glassdoor < /a > -- partnership Follows Kites Investment in Shorelines Recent Series a -- Opened with $ 17.00 in its Jun 27, 2014 IPO, a clinical-stage biopharmaceutical company, focuses on cure.